Search research articles
Contact Us
Filters
Showing results (471-480 of 596) with videos related to
Page
of 60
Sort By:
International Journal of Chronic Obstructive Pulmonary Disease
|
April 7, 2021
Association of Chronic Obstructive Pulmonary Disease with Morbidity and Mortality in Patients with Peripheral Artery Disease: Insights from the EUCLID Trial
Jemi Galani, Hillary Mulder, Frank W Rockhold, et al.
JACC. Cardiovascular Interventions
|
July 25, 2020
The Impact of Coronary Physiology on Contemporary Clinical Decision Making
Norihiro Kogame, Masafumi Ono, Hideyuki Kawashima, et al.
Radiology
|
September 12, 2023
Prognostic Value of Coronary CT Angiography-derived Fractional Flow Reserve on 3-year Outcomes in Patients with Stable Angina
Kristian T Madsen, Bjarne L Nørgaard, Kristian A Øvrehus, et al.
Circulation. Cardiovascular Interventions
|
February 27, 2026
Low-Dose Rivaroxaban Plus Aspirin in Patients With PAD Undergoing Lower Extremity Revascularization With and Without History of Prior Limb Revascularization: Insight From the VOYAGER-PAD Trial
Mario Enrico Canonico, Jessica Parr, E Sebastian Debus, et al.
The Journal of Thoracic and Cardiovascular Surgery
|
November 17, 2020
ACC/AATS/AHA/ASE/ASNC/SCAI/SCCT/STS 2017 appropriate use criteria for coronary revascularization in patients with stable ischemic heart disease: A report of the American College of Cardiology Appropriate Use Criteria Task Force, American Association for Thoracic Surgery, American Heart Association, American Society of Echocardiography, American Society of Nuclear Cardiology, Society for Cardiovascular Angiography and Interventions, Society of Cardiovascular Computed Tomography, and Society of Thoracic Surgeons
Manesh R Patel, John H Calhoon, Gregory J Dehmer, et al.
American Heart Journal
|
September 21, 2015
Efficacy and safety of rivaroxaban in patients with diabetes and nonvalvular atrial fibrillation: the Rivaroxaban Once-daily, Oral, Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF Trial)
Sameer Bansilal, Zachary Bloomgarden, Jonathan L Halperin, et al.
Journal of Medical Genetics
|
March 20, 2016
Time to treatment benefit for adult patients with Fabry disease receiving agalsidase β: data from the Fabry Registry
Alberto Ortiz, Ademola Abiose, Daniel G Bichet, et al.
Vascular Medicine (London, England)
|
July 12, 2018
Ticagrelor versus clopidogrel in patients with symptomatic peripheral artery disease and prior coronary artery disease: Insights from the EUCLID trial
Jeffrey S Berger, Beth L Abramson, Renato D Lopes, et al.
Circulation. Cardiovascular Quality and Outcomes
|
February 3, 2025
Quality of Life Outcomes With a Risk-Based Precision Testing Strategy Versus Usual Testing in Stable Patients With Suspected Coronary Disease: Results From the PRECISE Randomized Trial
Daniel B Mark, Yanhong Li, Michael G Nanna, et al.
Heart (British Cardiac Society)
|
February 19, 2016
Native valve disease in patients with non-valvular atrial fibrillation on warfarin or rivaroxaban
Günter Breithardt, Helmut Baumgartner, Scott D Berkowitz, et al.
Page
of 60
Search research articles
Search
Showing results (471-480 of 596) with videos related to
Sort By:
Page
of 60
International Journal of Chronic Obstructive Pulmonary Disease
|
April 7, 2021
Association of Chronic Obstructive Pulmonary Disease with Morbidity and Mortality in Patients with Peripheral Artery Disease: Insights from the EUCLID Trial
Jemi Galani, Hillary Mulder, Frank W Rockhold, et al.
JACC. Cardiovascular Interventions
|
July 25, 2020
The Impact of Coronary Physiology on Contemporary Clinical Decision Making
Norihiro Kogame, Masafumi Ono, Hideyuki Kawashima, et al.
Radiology
|
September 12, 2023
Prognostic Value of Coronary CT Angiography-derived Fractional Flow Reserve on 3-year Outcomes in Patients with Stable Angina
Kristian T Madsen, Bjarne L Nørgaard, Kristian A Øvrehus, et al.
Circulation. Cardiovascular Interventions
|
February 27, 2026
Low-Dose Rivaroxaban Plus Aspirin in Patients With PAD Undergoing Lower Extremity Revascularization With and Without History of Prior Limb Revascularization: Insight From the VOYAGER-PAD Trial
Mario Enrico Canonico, Jessica Parr, E Sebastian Debus, et al.
The Journal of Thoracic and Cardiovascular Surgery
|
November 17, 2020
ACC/AATS/AHA/ASE/ASNC/SCAI/SCCT/STS 2017 appropriate use criteria for coronary revascularization in patients with stable ischemic heart disease: A report of the American College of Cardiology Appropriate Use Criteria Task Force, American Association for Thoracic Surgery, American Heart Association, American Society of Echocardiography, American Society of Nuclear Cardiology, Society for Cardiovascular Angiography and Interventions, Society of Cardiovascular Computed Tomography, and Society of Thoracic Surgeons
Manesh R Patel, John H Calhoon, Gregory J Dehmer, et al.
American Heart Journal
|
September 21, 2015
Efficacy and safety of rivaroxaban in patients with diabetes and nonvalvular atrial fibrillation: the Rivaroxaban Once-daily, Oral, Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF Trial)
Sameer Bansilal, Zachary Bloomgarden, Jonathan L Halperin, et al.
Journal of Medical Genetics
|
March 20, 2016
Time to treatment benefit for adult patients with Fabry disease receiving agalsidase β: data from the Fabry Registry
Alberto Ortiz, Ademola Abiose, Daniel G Bichet, et al.
Vascular Medicine (London, England)
|
July 12, 2018
Ticagrelor versus clopidogrel in patients with symptomatic peripheral artery disease and prior coronary artery disease: Insights from the EUCLID trial
Jeffrey S Berger, Beth L Abramson, Renato D Lopes, et al.
Circulation. Cardiovascular Quality and Outcomes
|
February 3, 2025
Quality of Life Outcomes With a Risk-Based Precision Testing Strategy Versus Usual Testing in Stable Patients With Suspected Coronary Disease: Results From the PRECISE Randomized Trial
Daniel B Mark, Yanhong Li, Michael G Nanna, et al.
Heart (British Cardiac Society)
|
February 19, 2016
Native valve disease in patients with non-valvular atrial fibrillation on warfarin or rivaroxaban
Günter Breithardt, Helmut Baumgartner, Scott D Berkowitz, et al.
Page
of 60